RegulationFast Track (United States), Orphan Drug (United States), Orphan Drug (European Union), Rare Pediatric Disease (United States), Priority Review (United States), Breakthrough Therapy (United States)

Structure/Sequence

Molecular FormulaC21H27N5

InChIKeyWVLHHLRVNDMIAR-IBGZPJMESA-N

CAS Registry558447-26-0

Clinical Trials associated with Mavorixafor

NCT06858696

/ RecruitingPhase 1

An Open-label, Non-randomized Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.

Start Date28 Feb 2025

Sponsor / Collaborator

X4 Pharmaceuticals, Inc.

CTRI/2025/02/080276

/ Not yet recruitingPhase 3

A Phase 3 randomized double-blind placebo-controlled multicenter study of mavorixafor in participants with congenital and acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and or serious infections - X4P-001-110

Start Date25 Feb 2025

Sponsor / Collaborator

Novotech Clinical Research India Pvt Ltd.

NCT06914869

/ CompletedPhase 1

A Phase I, Randomized, Open-label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of a Moderate and a Strong CYP3A Inducer on the Pharmacokinetics and Safety of Mavorixafor in Healthy Male and Female Participants

The main purpose of this study is to evaluate drug-drug interaction (DDI) of orally administered mavorixafor with cytochrome P3A (CYP3A) inducers carbamazepine (a strong CYP3A inducer) or efavirenz (a moderate CYP3A inducer) in healthy male and female participants.

Start Date18 Feb 2025

Sponsor / Collaborator

X4 Pharmaceuticals, Inc.

100 Clinical Results associated with Mavorixafor

100 Translational Medicine associated with Mavorixafor

100 Patents (Medical) associated with Mavorixafor

Literatures (Medical) associated with Mavorixafor

01 Jun 2026·CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Understanding Pharmacokinetic-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2024 to Better Manage the Risk of Drug Interactions With Concomitant Medications: A Review of Clinical Data From New Drug Applications

Review

Author: Owens, Katie ; Argon, Sophie ; Yu, Jingjing ; Ragueneau-Majlessi, Isabelle ; Wang, Yan

Objective:

This analysis aimed to provide a mechanistic understanding and an evaluation of the clinical relevance of pharmacokinetic drug-drug interactions (DDIs) associated with drugs approved by the Food and Drug Administration in 2024.

Methods:

Drug metabolism, transport, and absorption-based DDI data available in New Drug Applications (NDAs) of small molecular drugs approved (n = 34) was analyzed. The mechanism and clinical outcome of these interactions were characterized based on in vitro, in silico, and clinical data.

Results:

As objects, 11 drugs were identified as clinical substrates. Of these, 7 drugs were substrates of CYP3A, 3 of CYP2C9, one of CYP1A2, and one of CYP2C8, including the sensitive substrates vanzacaftor (CYP3A) and vorasidenib (CYP1A2). As precipitants, 6 drugs (acoramidis, cefepime/enmetazobactam, givinostat, lazertinib, mavorixafor, and resmetirom) were clinical inhibitors of CYP enzymes (2C8, 2C9, 2D6, 2E1, and 3A), with mavorixafor being a CYP2D6 strong inhibitor. Two drugs (elafibranor and tovorafenib) showed weak induction of CYP3A. Regarding transporter data, 3 drugs were substrates of transporters, including seladelpar (BCRP and OAT3), sulopenem (OAT3), and vadadustat (OAT1/3), and 8 drugs (arimoclomol, danicopan, givinostat, lazertinib, mavorixafor, resmetirom, vadadustat, and vazacaftor/tezacaftor/deutivacaftor) were inhibitors of transporters. All clinical DDIs with AUC changes ≥ 2-fold triggered labeling recommendations. Several DDIs with an AUC change <2 also had labeling recommendations, pertaining most often to the concomitant use of drugs with a narrow therapeutic index.

Conclusions:

Mechanistic DDI insights from newly approved therapies can be extrapolated to inform the management of commonly co-administered drugs, supporting a safer and more effective use of new drug products in the context of polypharmacy.

02 Aug 2025·ChemMedChem

Synthesis and ⁶⁴Cu‐Radiolabeling Strategies of Small Organic Radioconjugates Based on the AMD070 Scaffold

Article

Author: Chérel, Michel ; Tripier, Raphaël ; Faivre‐Chauvet, Alain ; Le Saëc, Patricia ; Troadec, Thibault ; Le Roy, Marie M.

CXCR4 is a transmembrane receptor overexpressed in a large variety of cancer cells. In addition to classical antibody‐ and peptide‐targeting for the development of positron emission tomography (PET) radiopharmaceuticals, this receptor possesses a range of small organic inhibitors that can be exploited. These are based mainly on nitrogen‐rich scaffolds, such as AMD070, and cyclic polyamines, such as cyclam, in the AMD3100 skeleton. The latter has been explored as a direct 64Cu chelator, but examples of CXCR4 PET imaging with small organic targeting units are still scarce in the literature. Herein, the synthesis of two novel CXCR4‐directed radiopharmaceuticals is described, combining the AMD070 scaffold as a targeting unit and bifunctional te1pa macrocycle as a strong 64Cu chelator. The synthesis of the conjugates and optimization of 64Cu‐radiolabeling are presented, opening the way for future in vitro and in vivo studies.

04 May 2025·IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Mavorixafor: a CXCR4 antagonist for WHIM syndrome

Review

Author: Xu, Bo ; Chen, Jixiang ; Zhou, Jiecan ; Chen, Canyu ; Li, Weiyi ; He, Zunbo

BACKGROUND:

WHIM syndrome is a rare primary immune deficiency and chronic neutropenia caused by overactivation of the C-X-C motif chemokine receptor 4/C-X-C motif chemokine ligand 12 (CXCR4/CXCL12) signaling pathway. On April 26th, 2024, Xolremdi (mavorixafor) capsules received its approval from US FDA, is the first targeted treatment specifically for patients aged ≥12 years with WHIM syndrome. Mavorixafor, as a selective CXCR4 antagonist, is able to increase the number of mature neutrophils and lymphocytes in the blood.

OBJECTIVE:

This review is to describe the pharmacological properties of mavorixafor and evaluate its clinical efficacy and safety profile.

METHODS:

A literature search was conducted using keywords mavorixafor, XOLREMDI, AMD070, AMD11070, X4P-001, WHIM Syndrome, and CXCR4/CXCL12 on Web of Science, Google Scholar, and PubMed. Drug information was obtained from the FDA website.

RESULTS:

In the pivotal 52-week phase III trial, time above absolute neutrophil count threshold (TAT_ANC) values in the mavorixafor group were higher than those in the placebo group at 4 different time points (15.04 h vs 2.75 h; p < 0.0001), and mavorixafor group had lower infection frequency, severity and duration. The most common adverse events are thrombocytopenia, pityriasis, rash, rhinitis, epistaxis, vomiting, and dizziness.

CONCLUSION:

Mavorixafor 400mg daily effectively increases WBC count, reduces disease symptoms and infection burden in WHIM syndrome patients ≥12 years. Future clinical programs will continue to evaluate the safety and efficacy of mavorixafor in patients with chronic neutropenic disease.

148

News (Medical) associated with Mavorixafor

06 Jan 2026

·www.businesswire.com

Catalio-Backed Rhapsogen Names Renato Skerlj, Ph.D., Chief Executive Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Rhapsogen, an immunology company redefining the treatment paradigm for autoimmune diseases, today announced the appointment of Renato Skerlj, Ph.D., as the company’s new Chief Executive Officer, effective immediately. Rhapsogen was launched by Catalio Capital Management’s venture strategy earlier this year. The company was co-founded by Prof. Jeffrey Ravetch, M.D., Ph.D., of Rockefeller University, and Prof. Eric Sundberg, Ph.D. of Emory University, both of whom are leaders in the immunology field and have made fundamental contributions to the understanding of how the immune system interacts directly with antibodies to protect against infection or cause autoimmune disease. In addition to his primary appointment, Dr. Jeffery Ravetch is a Catalio Venture Partner. Dr. Skerlj is a seasoned biotechnology executive with more than 30 years of experience in drug discovery and development. He has authored over 70 scientific publications, is an inventor on more than 60 patents, and has played key leadership roles in advancing multiple therapeutics from discovery through clinical development and regulatory approval. Most recently, Dr. Skerlj served as President and Chief Executive Officer of Expansion Therapeutics, where he led the advancement of a proprietary RNA-targeting platform and overseeing company growth and financing. Previously, he was Co-Founder and Chief Scientific Officer of X4 Pharmaceuticals and a co-inventor of mavorixafor, which received FDA approval in 2024 for the treatment of WHIM syndrome. Across his career, Dr. Skerlj has built and led high-performing R&D organizations, contributed to successful financings and strategic transactions, and helped translate scientific innovation into impactful medicines. “I am very excited by what we are building at Rhapsogen and look forward to working with our world-class team of immunology experts to deliver the solutions that autoimmune patients need and deserve,” said Dr. Skerlj. “Dr. Skerlj’s leadership experience coupled with his deep drug development expertise make him well suited to maximize the potential of Rhapsogen’s first-in-class approach in autoimmune disease. We are thrilled to continue supporting the company’s growth under Dr. Skerlj’s leadership," said Matthew Hobson, Ph.D., Principal at Catalio Capital Management, who will be also joining Rhapsogen’s Board of Directors. About Rhapsogen Rhapsogen is a Cambridge, MA-based immunology company focused on redefining the autoimmune treatment paradigm by developing next generation therapies that rapidly neutralize pathogenic autoantibodies and prevent autoimmune inflammation and tissue damage while preserving the immune system’s ability to fight infection. The company was founded in 2025 by Dr. Jeffrey Ravetch (Rockefeller University) and Dr. Eric Sundberg (Emory University). To learn more, please visit www.rhapsogen.com. About Catalio Capital Management, LP: Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public and credit markets. Catalio has exclusive partnerships with world-renowned serial scientist-entrepreneurs from around the globe who each have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research. Catalio has offices in New York, London, and Washington, D.C. Learn more about Catalio Capital Management by visiting www.cataliocapital.com.

Executive Change

27 Oct 2025

·investors.x4pharma.com

X4 Pharmaceuticals Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $155.3 Million

BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the closing of its previously announced underwritten public offering of 52,844,000 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 6,984,000 additional shares, at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to X4 from the offering were approximately $155.3 million before deducting underwriting discounts and commissions and other offering expenses payable by X4. The total shares outstanding after giving effect to the offering was 79,214,708. All of the securities were offered by X4. Leerink Partners, Stifel and Guggenheim Securities acted as joint bookrunning managers for the offering. A shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on August 14, 2023 and became effective on August 24, 2023. This offering was made only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC, are available on the SEC’s website at www.sec.gov and may be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525 ext. 6105, or by emailing syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by emailing syndprospectus@stifel.com; or Guggenheim Securities, LLC at 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About X4 Pharmaceuticals X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The Company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. X4 Investor Contact: IR@X4pharma.com

Phase 3

24 Oct 2025

·investors.x4pharma.com

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

BOSTON, Oct. 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR) (“X4” or the “Company”), a company driven to improve the lives of people with rare hematology diseases, today announced the pricing of its previously announced underwritten public offering of 45,860,000 shares of its common stock at a public offering price per share of $2.90 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 700,000 shares of its common stock at a public offering price of $2.899 per pre-funded warrant. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immediately. The aggregate gross proceeds to X4 from the offering are expected to be approximately $135 million before deducting underwriting discounts and commissions and other offering expenses payable by X4, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on October 27, 2025, subject to the satisfaction of customary closing conditions. In addition, X4 has granted the underwriters an option for a period of 30 days to purchase up to an additional 6,984,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are being offered by X4. X4 intends to use the net proceeds from this offering, together with its existing cash and cash equivalents and cash flows from operations, to fund the pivotal Phase 3 development of mavorixafor in certain chronic neutropenic disorders, as well as for general and administrative expenses, capital expenditures, working capital and other general corporate purposes. Leerink Partners, Stifel and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering. A shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on August 14, 2023 and became effective on August 24, 2023. This offering is being made only by means of a written prospectus, including a prospectus supplement, forming a part of the effective registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov and, when available, may be obtained from: Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525 ext. 6105, or by emailing syndicate@leerink.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, California 94104, by telephone at (415) 364-2720 or by emailing syndprospectus@stifel.com; or Guggenheim Securities, LLC at 330 Madison Avenue, 8th Floor, New York, NY 10017, Attention: Equity Syndicate Department, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About X4 Pharmaceuticals X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare hematology diseases and significant unmet needs. Leveraging expertise in CXCR4, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is currently being marketed in the U.S. as XOLREMDI® in its first indication. The Company is also evaluating additional uses of mavorixafor and is conducting a global, pivotal Phase 3 clinical trial (4WARD) in people with certain chronic neutropenic disorders. X4 is headquartered in Boston, Massachusetts. X4 Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by the words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target,” or other similar terms or expressions that concern X4’s expectations, strategy, business, plans, or intentions. Forward-looking statements include, without limitation, implied or express statements regarding: X4’s expectations regarding the consummation of the offering, the anticipated use of proceeds from the offering, the satisfaction of customary closing conditions with respect to the offering and the potential value and clinical benefit of the Company’s product candidates. Any forward-looking statements in this press release are based on management’s current expectations and beliefs. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond X4’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements, including the risks that: X4 may be unable to advance and commercialize mavorixafor to treat chronic neutropenia or to gain ex-U.S. approval for the treatment of WHIM; the expected sufficiency of X4’s existing cash resources and runway may not be accurate; the expected availability, content, and timing of clinical data from X4’s ongoing clinical trials of mavorixafor may be delayed or unavailable, including the ongoing Phase 3 clinical trial in chronic neutropenia; trials, studies and research programs may not have satisfactory outcomes; earlier trials and studies may not be predictive of later trials and studies; the design and rate of enrollment for clinical trials, including the ongoing Phase 3 clinical trial evaluating mavorixafor in certain chronic neutropenic disorders may not enable successful completion of the trial(s); the commercial opportunity for mavorixafor in chronic neutropenic disorders may be smaller than anticipated; X4 may be unable to obtain and maintain regulatory approvals; adverse safety effects may arise from the testing or use of the Company’s product and product candidates; and other risks and uncertainties, including those described in the section entitled “Risk Factors” in X4’s most recent Annual Report on Form 10-K filed with the SEC and in subsequent filings X4 makes with the SEC from time to time. X4 undertakes no obligation to update the information contained in this presentation to reflect new events or circumstances, except as required by law. X4 Investor Contact: IR@X4pharma.com

Phase 3

100 Deals associated with Mavorixafor

External Link

KEGG	Wiki	ATC	Drug Bank
D11510	-	-	DB05501

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
WHIM Syndrome	United States	X4 Pharmaceuticals, Inc.	26 Apr 2024

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immunodeficiency congenital	Phase 3	United States	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	Australia	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	Denmark	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	France	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	Italy	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	Netherlands	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	Russia	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	South Korea	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	Spain	X4 Pharmaceuticals, Inc.	12 Jan 2026
Immunodeficiency congenital	Phase 3	United Kingdom	X4 Pharmaceuticals, Inc.	12 Jan 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


PS1654 (EHA2025)	Phase 2	Neutropenia	-	Mavorixafor alone	ysknfzrhdu(grxrvxijyo) = The most frequently reported treatment-related, treatment-emergent adverse events were gastrointestinal, all of mild or moderate severity rlqbllznpx (acbqtyhwsz ) View more	Positive	14 May 2025
				Mavorixafor plus G-CSF
NCT04154488 (GlobeNewswire) Manual	Phase 2	Neutropenia	23	Mavorixafor monotherapyMavorixafor monotherapy	yvduadfnet(hpkqezpdcx) = blgycvqvrw llynfdyarg (kaqeqbmfix )	Positive	13 Nov 2024
				Mavorixafor in combination with injectable G-CSFMavorixafor in combination with injectable G-CSF	yvduadfnet(hpkqezpdcx) = khhamsujny llynfdyarg (kaqeqbmfix )
NCT03005327 (CTgov)	Phase 2	WHIM Syndrome	8	X4P-001 (X4P-001 50 mg)	ihzukfkwlh(ujeqtoofnm) = wzwnfomidg lfddzfqnfp (wzvogjgluv, 156.094) View more	-	30 Oct 2024
				X4P-001 (X4P-001 100 mg)	ihzukfkwlh(ujeqtoofnm) = uefkiblvfz lfddzfqnfp (wzvogjgluv, 4238.280) View more
NCT02667886 (X4P-001-RCCA, CTgov)	Phase 1/2	Advanced Renal Cell Carcinoma	74	X4P-001+Axitinib (X4P-001 200 mg BID With Axitinib)	nsedbjqnmn = psonpubqvf vnmzjmzxbp (orosezujzw, jdqpjtnjmn - ppectzdlcx) View more	-	14 Aug 2024
				X4P-001+Axitinib (X4P-001 400 mg QD With Axitinib)	nsedbjqnmn = kjimvxvgic vnmzjmzxbp (orosezujzw, snlnikrhjd - zagixmvsmu) View more
NCT03995108 (phase 3, Pubmed \| Blood)	Phase 3	WHIM Syndrome CXCR4 gain-of-function variants	31	Mavorixafor	bwlzecjahr(iqdehezoez) = vuytarijej dmffjhtzon (jilwhhhxgf ) View more	Positive	04 Jul 2024
				Placebo	bwlzecjahr(iqdehezoez) = znxwktwchw dmffjhtzon (jilwhhhxgf ) View more
NCT04154488 (Biospace) Manual	Phase 2	Neutropenia	23	Mavorixafor monotherapy	ugtvwurhhp(lkvbmwxwhg) = qundnxhdbf zoxdgtwanx (qfznjhmqul ) View more	Positive	27 Jun 2024
				Mavorixafor with stable-dose G-CSF	qtgeoviouj(bicifuybff) = wnqvgostvb vbryaeexjb (typzquhnak )
NCT03995108 (FDA_CDER) Manual	Phase 3	WHIM Syndrome	31	XOLREMDI	mzxahodkbx(wvncdkgnvy) = qffcebdnza slhexblztl (vpgvrivqyg, 1.89) View more	Positive	26 Apr 2024
NCT03995108 (Phase 3 Trial of an Oral CXCR4 Antagonist, AAAAI2024)	Phase 3	WHIM Syndrome	-	Mavorixafor	dhsbxwvwiy(sdodlpevwo) = jbhrcdnrst qvazjxcvle (qxeyilexxs ) View more	Positive	23 Feb 2024
				Placebo	dhsbxwvwiy(sdodlpevwo) = shsbddufhc qvazjxcvle (qxeyilexxs ) View more
NCT03995108 (EHA2023)	Phase 3	WHIM Syndrome	31	Mavorixafor	joezjmsuru(mugtmqwrql) = increased from baseline into normal range and sustained at each timepoint assessed over 52 weeks with mavorixafor versus placebo gbarbluzwp (qgupjospyj ) View more	Positive	08 Jun 2023
				Placebo
NCT02923531 (CTgov)	Phase 1/2	Locally Advanced Clear Cell Renal Cell Carcinoma	9	Nivolumab+X4P-001	ouptmtzwzk = wumporhoen vssouwuesl (fecqcdslac, jotdpwwzsf - xeixtkgjnz) View more	-	29 Dec 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis